A phase 2 randomized, double-blinded (BMS-562247 [apixaban] and enoxaparin), active-controlled (enoxaparin and warfarin), parallel-arm, dose-response study of the oral factor Xa inhibitor BMS-562247 in subjects undergoing elective total knee replacement surgery
Latest Information Update: 18 Nov 2012
At a glance
- Drugs Apixaban (Primary) ; Enoxaparin sodium; Warfarin
 - Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
 - Focus Registrational; Therapeutic Use
 - Acronyms APROPOS
 
Most Recent Events
- 07 Nov 2012 Planned number of patients changed from 1202 to 1666 as reported by European Clinical Trials Database.
 - 17 Jan 2007 Status change
 - 06 Nov 2005 New trial record.